Mesenchymal Stem Cells in Clinical Trials for Immune Disorders

Authors' Contributions

Z.L. wrote the paper, and Z.H. and Z.C.H. revised and approved the final manuscript.

Funding

This work was supported by grants from the Tianjin Natural Science Foundation (21JCZDJC00070, 22JCZXJC00170) and the Nankai University Eye Institute (NKYKD202203).

Conflict of Interest

None declared.

References

[1] Li Z, Han ZC. Introduction of perinatal tissue-derived stem cells. In: Han ZC, Takahashi TA, Li Z. eds. Perinatal Stem Cells: Biology, Manufacturing and Translational Medicine. Singapore; Springer Singapore; 2019: 1-7

[2] Ji YR, Yang ZX, Han Z-B, et al. Mesenchymal stem cells support proliferation and terminal differentiation of B cells. Cell Physiol Biochem 2012; 30[phone]

[3] Zhao Q, Han Z, Wang J, Han Z. Development and investigational new drug application of mesenchymal stem/stromal cells products in China. Stem Cells Transl Med 2021; 10(Suppl. 02) S18-S30

[4] Hezam K, Fu E, Zhang J, Li Z. Therapeutic trends of priming mesenchymal stem cells: a bibliometric analysis. Biochem Biophys Rep 2024; 38: 101708

[5] Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol 2018; 14[phone]

[6] Chen Y, Xu Y, Chi Y, et al. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial. Signal Transduct Target Ther 2024; 9(01) 102

[7] Chen H. Stem cell translational medicine: the Tianjin model revisited. Stem Cells Transl Med 2021; 10(Suppl. 02) S4-S9

[8] Fang L, Meikuang L, Ye G, et al. Successful treatment of a 19-month-old boy with hepatitis associated aplastic anemia by infusion of umbilical cord-derived mesenchymal stromal cells: a case report. Cell Transplant 2021; 30: 963689720977144

[9] Han ZC, Takahashi TA, Han Z, Li Z. Perinatal Stem Cells. Singapore:: Springer; 2019

[10] Liang W, Chen X, Zhang S, et al. Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines. Cell Mol Biol Lett 2021; 26(01) 3

[11] Du WJ, Chi Y, Yang ZX, et al. Heterogeneity of proangiogenic features in mesenchymal stem cells derived from bone marrow, adipose tissue, umbilical cord, and placenta. Stem Cell Res Ther 2016; 7(01) 163

[12] Huang Y, Wu Q, Tam PKH. Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications. Int J Mol Sci 2022; 23(17) 10023

[13] Cao X, Duan L, Hou H, et al. IGF-1C hydrogel improves the therapeutic effects of MSCs on colitis in mice through PGE₂-mediated M2 macrophage polarization. Theranostics 2020; 10(17) 7697-7709

[14] Huang A, Liu Y, Qi X, et al. Intravenously transplanted mesenchymal stromal cells: a new endocrine reservoir for cardioprotection. Stem Cell Res Ther 2022; 13(01) 253

[15] Wysoczynski M, Khan A, Bolli R. New paradigms in cell therapy: repeated dosing, intravenous delivery, immunomodulatory actions, and new cell types. Circ Res 2018; 123[phone]

[16] Leibacher J, Henschler R. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther 2016; 7: 7

RIGHTS & PERMISSIONS

Global Medical Genetics